Tailored for you

In-depth Analysis Tailored to Specified Regions or Segments
Company Profiles Customized to User Preferences
Comprehensive Insights Focused on Specific Segments or Regions

+1 2315155523

Blood Stream Infection Testing Market: $7.11B, 8.3% CAGR

Blood Stream Infection Testing Market

Blood Stream Infection Testing Market: $7.11B, 8.3% CAGR

Blood Stream Infection Testing Market by Product (Instruments, Consumables, Software and Services), by Technique (Conventional, Automated), by Technology (Culture-based, Molecular, Proteomic), by Application (Bacterial, Fungal, Mycobacterial), by End-users (Hospitals, Independent Diagnostics Centers, Others), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific) Forecast 2026-2034

Updated On : May 25, 2026|Base Year : 2025|Pages : 180

Key Insights into the Blood Stream Infection Testing Market

The global Blood Stream Infection Testing Market is currently valued at $7.11 billion and is projected to expand at a compound annual growth rate (CAGR) of 8.3% through 2033, reflecting robust systemic demand driven by rising incidence of sepsis, antimicrobial resistance proliferation, and accelerating adoption of rapid diagnostic platforms across acute care settings worldwide. The market's strategic trajectory is underpinned by a convergence of clinical urgency, technological disruption, and regulatory prioritization across major geographies.

Blood Stream Infection Testing Market Research Report - Market Overview and Key Insights — Blood Stream Infection Testing Market Market Size (In Billion)

Bloodstream infections (BSIs) remain among the most life-threatening healthcare-associated complications, with sepsis attributable mortality rates still exceeding 25–30% globally when diagnosis is delayed beyond the critical six-hour intervention window. This epidemiological reality is a primary catalyst compelling hospitals and independent diagnostic centers to invest in faster, more accurate testing systems. The WHO's Global Antimicrobial Resistance Action Plan, combined with growing stewardship programs across Europe, North America, and Asia Pacific, has further elevated diagnostic speed and specificity as institutional imperatives.

Blood Stream Infection Testing Market Market Size and Forecast (2024-2030) — Blood Stream Infection Testing Market Company Market Share

From a product standpoint, the instruments segment leads current revenue generation, while consumables represent the highest recurring revenue stream, ensuring sustained market momentum even during capital expenditure cycles. Software and services are emerging as a rapidly growing component as laboratory informatics and AI-assisted interpretation gain clinical traction.

Technological segmentation reveals a decisive pivot toward molecular and proteomic methodologies, with culture-based techniques retaining dominance in volume but losing share to faster alternatives. The integration of mass spectrometry, nucleic acid amplification, and next-generation sequencing-based approaches into clinical workflows is reshaping turnaround time expectations from 48–72 hours to under six hours for many pathogens.

Geographically, North America commands the largest market share, supported by advanced healthcare infrastructure, reimbursement frameworks, and high rates of healthcare-associated infections. Asia Pacific, however, is emerging as the highest-growth region, driven by expanding hospital networks, government infection control mandates, and rising diagnostic awareness in China, India, and ASEAN nations.

Forward-looking, the market is expected to surpass $14 billion by 2033, with pipeline innovations in syndromic panel testing, CRISPR-based detection, and AI-integrated diagnostic platforms set to redefine clinical standards. Strategic consolidation among major players and increasing venture capital inflows into precision microbiology startups will further accelerate competitive intensity and technological differentiation through the forecast horizon.

Dominance of Molecular Technology Segment in Blood Stream Infection Testing Market

Within the Blood Stream Infection Testing Market, the molecular technology segment has emerged as the single largest and most strategically consequential sub-segment by revenue share, displacing conventional culture-based methods as the clinical gold standard in high-acuity settings. Molecular diagnostics deliver pathogen identification and antimicrobial resistance profiling within two to six hours, compared to the 48–72-hour minimum required by traditional blood culture systems, a differentiation that directly correlates with improved patient survival outcomes and reduced inappropriate antibiotic use.

The dominance of molecular testing is reinforced by the clinical validation landscape: multiple large-scale prospective studies have demonstrated that molecular panel assays — particularly polymerase chain reaction (PCR)-based and multiplex syndromic panels — reduce time-to-targeted therapy by an average of 24–36 hours, directly impacting sepsis mortality rates and ICU length of stay. In high-income healthcare systems where hospital-acquired infection costs are quantified and penalized, this efficiency translates directly into institutional ROI calculations favoring capital investment in molecular platforms.

Multiplex PCR platforms from companies including bioMérieux SA, Luminex Corporation, and Accelerate Diagnostics Inc. have achieved broad clinical adoption across Tier 1 hospital systems in North America and Europe. The BioFire FilmArray Blood Culture Identification panel, for example, can simultaneously identify over 27 pathogens and 10 resistance genes within approximately 1.5 hours of positive blood culture flagging, representing a paradigmatic shift in post-culture workflow.

Proteomic technologies, particularly matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, represent a complementary sub-layer within the molecular-adjacent space. Bruker Corporation and bioMérieux SA lead this segment. MALDI-TOF achieves species-level identification in 10–15 minutes directly from positive blood culture material, making it a standard-of-care tool in well-resourced microbiology laboratories globally.

The molecular segment's share consolidation is further accelerated by the declining cost of reagent panels, increased FDA and CE-IVD clearances for expanded target panels, and growing penetration into mid-tier hospital systems that previously relied exclusively on culture-based workflows. Between 2021 and 2024, the number of FDA-cleared blood culture molecular identification assays increased by approximately 40%, signaling regulatory confidence and commercial pipeline richness.

Key competitive dynamics within this segment center on panel breadth, turnaround time, ease of integration with laboratory information systems (LIS), and total cost of ownership. Players are actively investing in direct-from-whole-blood molecular assays that bypass the culture step entirely — a technology category that, if commercialized at scale, could structurally disrupt the current two-step diagnostic paradigm and further entrench molecular testing as the market's dominant revenue engine.

The molecular diagnostics space within BSI testing is also closely intertwined with the broader Molecular Diagnostics Market, which provides critical R&D infrastructure, platform technologies, and economies of scale that benefit BSI-specific product development pipelines.

Blood Stream Infection Testing Market Market Share by Region - Global Geographic Distribution — Blood Stream Infection Testing Market Regional Market Share

Key Market Drivers and Constraints in Blood Stream Infection Testing Market

The Blood Stream Infection Testing Market is shaped by a series of quantifiable structural drivers and identifiable constraints that collectively define its 8.3% CAGR trajectory through 2033.

Driver 1 — Rising Sepsis Incidence: The Global Sepsis Alliance estimates approximately 49 million sepsis cases annually, with 11 million fatalities, representing 20% of all global deaths. Each percentage-point improvement in early BSI detection translates into measurable reductions in ICU admissions, a direct demand driver for rapid testing platforms.

Driver 2 — Antimicrobial Resistance Escalation: WHO's 2023 AMR Global Action Plan identifies bloodstream infections caused by carbapenem-resistant Enterobacteriaceae and MRSA as priority pathogens. Resistance profiling now constitutes a mandatory clinical workflow in many national health systems, driving simultaneous demand for both identification and resistance gene detection assays, directly benefiting the Antimicrobial Resistance Testing Market and BSI testing platforms.

Driver 3 — Healthcare-Associated Infection (HAI) Regulatory Pressure: The U.S. Centers for Medicare & Medicaid Services (CMS) has linked hospital reimbursement penalties to central line-associated bloodstream infection (CLABSI) rates since 2012, creating sustained institutional purchasing incentives for faster diagnostic turnaround. Similar frameworks exist across EU member states under the ECDC HAI surveillance mandate.

Driver 4 — Technological Accessibility: The average selling price of multiplex PCR BSI panels declined by approximately 15–20% between 2019 and 2024, expanding addressable market reach into secondary care hospitals and independent diagnostic centers in emerging markets.

Constraint 1 — Reimbursement Fragmentation: In Asia Pacific and Latin America, reimbursement coverage for advanced molecular BSI panels remains inconsistent, limiting market penetration despite strong clinical need. Out-of-pocket cost sensitivity in lower-middle-income countries constrains volume growth in these high-population regions.

Constraint 2 — Workflow Integration Complexity: Adoption of molecular panels requires LIS connectivity, trained personnel, and controlled laboratory environments — infrastructure gaps that create friction in under-resourced settings and slow the transition away from culture-based methods in secondary care.

Competitive Ecosystem of Blood Stream Infection Testing Market

The competitive landscape of the Blood Stream Infection Testing Market is characterized by a mix of large diagnostics conglomerates, specialized molecular diagnostics firms, and emerging technology companies, each pursuing differentiated strategies across product categories and geographies.

Abbott Laboratories: A global diagnostics leader with a broad infectious disease portfolio, Abbott leverages its ARCHITECT and Alinity platforms for multiplex molecular testing, maintaining strong hospital system relationships across North America and Europe through integrated diagnostics solutions.
Luminex Corporation: Specializing in multiplexing technologies, Luminex's xTAG and ARIES platforms support syndromic BSI panel testing; the company's acquisition by DiaSorin has expanded its commercial reach and manufacturing scale in molecular diagnostics for critical care.
bioMérieux SA: A dominant force in clinical microbiology, bioMérieux's BioFire FilmArray Blood Culture Identification panels are considered market-defining products; the company also leads in MALDI-TOF and automated blood culture systems through its BACT/ALERT platform family.
AdvanDx: A pioneer in PNA FISH (peptide nucleic acid fluorescence in situ hybridization) technology for rapid BSI organism identification directly from positive blood cultures, targeting rapid species differentiation in Staphylococcus and Candida species.
Cepheid: Known for its GeneXpert rapid molecular diagnostic platform, Cepheid has extended its near-patient testing capabilities into BSI-relevant pathogen panels, with particular strength in MRSA and C. difficile detection across hospital settings.
F. Hoffmann-La Roche Ltd.: Roche's molecular diagnostics division supports BSI testing through cobas and LightCycler platform integrations, with pipeline emphasis on automation, throughput scalability, and digital pathology connectivity across high-volume reference laboratories.
Bruker Corporation: A leader in MALDI-TOF mass spectrometry systems, Bruker's MALDI Biotyper platform is deployed in thousands of clinical microbiology laboratories globally, offering rapid species-level identification from positive blood culture material.
Thermo Fisher Scientific: Through its Applied Biosystems and Ion Torrent divisions, Thermo Fisher is advancing next-generation sequencing-based approaches to BSI diagnostics, positioning for clinical whole-genome sequencing workflows in resistance profiling.
Becton Dickinson Medical Devices Co. Ltd.: Becton Dickinson's BD BACTEC blood culture system remains among the most widely deployed automated culture platforms globally, with ongoing integration of molecular identification add-on workflows and digital connectivity through BD Kiestra.
Accelerate Diagnostics Inc.: A technology innovator offering the Accelerate Pheno system, which delivers rapid phenotypic antimicrobial susceptibility testing directly from positive blood cultures in approximately 7 hours, addressing a critical clinical gap between identification and therapy optimization.

Recent Developments & Milestones in Blood Stream Infection Testing Market

January 2023: bioMérieux SA received expanded CE-IVD marking for its BioFire FilmArray Blood Culture Identification 2 (BCID2) panel, adding coverage for additional Gram-negative resistance markers including OXA-48-like carbapenemase genes, strengthening its AMR profiling capability.
March 2023: Accelerate Diagnostics Inc. announced a strategic distribution partnership with a major European in vitro diagnostics distributor to expand Accelerate Pheno system placements across Central and Eastern European acute care hospitals.
June 2023: Thermo Fisher Scientific unveiled its Ion Torrent Genexus Integrated Sequencer enhancements targeting clinical metagenomics workflows for bloodstream infection pathogen identification, signaling NGS-based BSI diagnostics commercialization intent.
September 2023: Becton Dickinson received FDA 510(k) clearance for an updated BD BACTEC FX400 automation interface module, improving throughput and positive culture flagging speed in high-volume clinical laboratory settings.
February 2024: Abbott Laboratories announced integration of its Alinity m molecular platform with AI-assisted result interpretation software for polymicrobial BSI panel results, targeting reduction in diagnostic ambiguity in complex clinical presentations.
May 2024: Bruker Corporation reported a 12% year-over-year increase in MALDI Biotyper clinical system placements globally, driven particularly by hospital network expansions in India, Brazil, and Southeast Asia.
October 2024: The U.S. Centers for Disease Control and Prevention (CDC) updated its Bloodstream Infection prevention guidelines, explicitly recommending rapid molecular panel testing as a standard-of-care complement to blood culture in ICU settings, providing a regulatory tailwind for technology adoption.

Regional Market Breakdown for Blood Stream Infection Testing Market

The Blood Stream Infection Testing Market exhibits pronounced regional heterogeneity in maturity, growth trajectory, and dominant technology preference, shaped by healthcare infrastructure, reimbursement policy, and epidemiological profiles.

North America leads the global market, accounting for approximately 38–40% of total revenue. The United States anchors this dominance through comprehensive hospital accreditation requirements, CMS CLABSI penalty frameworks, and deep penetration of automated blood culture and molecular panel systems. The regional CAGR is estimated at 7.2% through 2033, reflecting a mature but still-expanding market supported by continuous technology upgrades and consumable replacement cycles. Canada and Mexico contribute incrementally, with Canadian provincial health systems increasingly mandating rapid molecular diagnostics in tertiary care.

Europe represents approximately 26–28% of global market value, with Germany, the United Kingdom, and France as primary revenue contributors. The ECDC's mandatory HAI surveillance network creates systematic demand for standardized BSI diagnostic platforms. European market CAGR is projected at approximately 6.8%, reflecting steady adoption of MALDI-TOF and multiplex PCR technologies across both public and private hospital systems. The Nordics demonstrate particularly high molecular testing penetration rates.

Asia Pacific is the fastest-growing regional segment, with an estimated CAGR of 10.5–11.0% through 2033, driven by China's hospital infrastructure expansion under its Healthy China 2030 initiative, India's growing private diagnostics sector, and increasing BSI awareness in ASEAN nations. Japan and South Korea maintain advanced clinical microbiology capabilities comparable to Western markets. The region's absolute value contribution is expected to surpass Europe by 2030 at current growth trajectories.

Middle East & Africa presents a heterogeneous landscape. GCC nations, led by Saudi Arabia and the UAE, are investing heavily in hospital-grade molecular diagnostics infrastructure, while Sub-Saharan Africa remains predominantly reliant on culture-based methods due to cost and cold-chain constraints. The regional CAGR is approximately 7.8%, with North Africa demonstrating accelerating growth through hospital privatization trends.

South America, led by Brazil and Argentina, maintains a CAGR of approximately 7.5%, supported by expanding public health laboratory networks and increasing penetration of automated blood culture systems in metropolitan tertiary care facilities.

Sustainability & ESG Pressures on Blood Stream Infection Testing Market

ESG considerations are increasingly shaping procurement decisions, product design mandates, and investor evaluations within the Blood Stream Infection Testing Market, a segment historically less scrutinized on environmental grounds than industrial sectors but now facing material pressure across multiple sustainability dimensions.

Single-use plastics constitute a significant material input in blood culture bottles, PCR reagent cartridges, and sample collection consumables. Major diagnostics manufacturers are under growing investor and regulatory pressure — particularly from EU Taxonomy Regulation alignment requirements and Scope 3 emissions disclosure frameworks — to quantify and reduce plastic waste generated per diagnostic cycle. Companies including Roche and Thermo Fisher Scientific have published formal product lifecycle assessment programs, while bioMérieux has committed to 30% reduction in packaging waste intensity by 2030 under its "One Health" ESG framework.

Carbon footprint reduction in laboratory operations is becoming a procurement criterion in European public hospital tenders. Energy consumption of automated blood culture incubators and molecular diagnostic systems is being incorporated into total cost of ownership models, incentivizing manufacturers to develop lower-wattage, higher-throughput instruments. This dynamic is reshaping instrument engineering specifications across the product development pipeline.

Circular economy mandates in Germany, France, and Scandinavian markets are driving demand for reagent container take-back programs

Blood Stream Infection Testing Market Segmentation

1. Product
- 1.1. Instruments
- 1.2. Consumables
- 1.3. Software and Services
2. Technique
- 2.1. Conventional
- 2.2. Automated
3. Technology
- 3.1. Culture-based
- 3.2. Molecular
- 3.3. Proteomic
4. Application
- 4.1. Bacterial
- 4.2. Fungal
- 4.3. Mycobacterial
5. End-users
- 5.1. Hospitals
- 5.2. Independent Diagnostics Centers
- 5.3. Others

Blood Stream Infection Testing Market Segmentation By Geography

1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
2. South America
- 2.1. Brazil
- 2.2. Argentina
- 2.3. Rest of South America
3. Europe
- 3.1. United Kingdom
- 3.2. Germany
- 3.3. France
- 3.4. Italy
- 3.5. Spain
- 3.6. Russia
- 3.7. Benelux
- 3.8. Nordics
- 3.9. Rest of Europe
4. Middle East & Africa
- 4.1. Turkey
- 4.2. Israel
- 4.3. GCC
- 4.4. North Africa
- 4.5. South Africa
- 4.6. Rest of Middle East & Africa
5. Asia Pacific
- 5.1. China
- 5.2. India
- 5.3. Japan
- 5.4. South Korea
- 5.5. ASEAN
- 5.6. Oceania
- 5.7. Rest of Asia Pacific

Blood Stream Infection Testing Market Regional Market Share

Higher Coverage

Lower Coverage

No Coverage

Blood Stream Infection Testing Market REPORT HIGHLIGHTS

Methodology

Our rigorous research methodology combines multi-layered approaches with comprehensive quality assurance, ensuring precision, accuracy, and reliability in every market analysis.

Quality Assurance Framework

Comprehensive validation mechanisms ensuring market intelligence accuracy, reliability, and adherence to international standards.

Multi-source Verification

500+ data sources cross-validated

Expert Review

200+ industry specialists validation

Standards Compliance

NAICS, SIC, ISIC, TRBC standards

Real-Time Monitoring

Continuous market tracking updates

Choose License Type

Tailored for you

In-depth Analysis Tailored to Specified Regions or Segments
Company Profiles Customized to User Preferences
Comprehensive Insights Focused on Specific Segments or Regions
Customized Evaluation of Competitive Landscape to Meet Your Needs
Tailored Customization to Address Other Specific Requirements

As requested- presale engagement was good, your perseverance, support and prompt responses were noted. Your follow up with vm’s were much appreciated. Happy with the final report and post sales by your team.

I have received the report already. Thanks you for your help.it has been a pleasure working with you. Thank you again for a good quality report

The response was good, and I got what I was looking for as far as the report. Thank you for that.

About Market Lens IQ

Market Lens IQ is a global market intelligence and strategic consulting firm delivering advanced syndicated research reports, customized industry analysis, competitive intelligence, and data-driven advisory solutions to organizations across international markets. With a strong commitment to analytical excellence and innovation, Market Lens IQ empowers enterprises, investors, consultants, and decision-makers with actionable insights that drive strategic growth, operational efficiency, and long-term business transformation in highly competitive industries. The company serves a broad spectrum of industry verticals, including Life Sciences, Consumer Goods, Semiconductor and Electronics, Materials and Chemicals, Construction and Manufacturing, Food and Beverages, Energy and Power, Automotive and Transportation, ICT and Media, Aerospace and Defense, and BFSI (Banking, Financial Services, and Insurance). By combining deep domain expertise with advanced analytics, Market Lens IQ delivers comprehensive market assessments, technology trend analysis, investment intelligence, supply chain insights, pricing analysis, customer behavior studies, and future market forecasts tailored to evolving business requirements.

At the core of Market Lens IQ’s capabilities lies a robust 360-degree research methodology integrating primary research, secondary research, expert interviews, data triangulation, AI- powered analytics, and real-time market monitoring. Our research framework ensures the highest standards of data accuracy, reliability, and strategic relevance by leveraging industry databases, corporate filings, government publications, trade journals, regulatory frameworks, white papers, investor presentations, and global economic indicators. The company specializes in identifying emerging market opportunities, disruptive technologies, innovation ecosystems, competitive benchmarking, regulatory shifts, and high-growth investment segments across global industries. Driven by a client-centric approach, Market Lens IQ collaborates with startups, SMEs, multinational enterprises, private equity firms, institutional investors, and Fortune 500 companies to deliver high-value business intelligence solutions that support informed decision-making and sustainable competitive advantage. Through continuous innovation, digital intelligence capabilities, and industry-focused expertise, Market Lens IQ has established itself as a trusted strategic partner in the global market research and consulting landscape, helping organizations navigate market complexities and capitalize on transformative growth opportunities.

Key Insights into the Blood Stream Infection Testing Market

Dominance of Molecular Technology Segment in Blood Stream Infection Testing Market

Key Market Drivers and Constraints in Blood Stream Infection Testing Market

The Blood Stream Infection Testing Market is shaped by a series of quantifiable structural drivers and identifiable constraints that collectively define its 8.3% CAGR trajectory through 2033.

Competitive Ecosystem of Blood Stream Infection Testing Market

Abbott Laboratories: A global diagnostics leader with a broad infectious disease portfolio, Abbott leverages its ARCHITECT and Alinity platforms for multiplex molecular testing, maintaining strong hospital system relationships across North America and Europe through integrated diagnostics solutions.
Luminex Corporation: Specializing in multiplexing technologies, Luminex's xTAG and ARIES platforms support syndromic BSI panel testing; the company's acquisition by DiaSorin has expanded its commercial reach and manufacturing scale in molecular diagnostics for critical care.
bioMérieux SA: A dominant force in clinical microbiology, bioMérieux's BioFire FilmArray Blood Culture Identification panels are considered market-defining products; the company also leads in MALDI-TOF and automated blood culture systems through its BACT/ALERT platform family.
AdvanDx: A pioneer in PNA FISH (peptide nucleic acid fluorescence in situ hybridization) technology for rapid BSI organism identification directly from positive blood cultures, targeting rapid species differentiation in Staphylococcus and Candida species.
Cepheid: Known for its GeneXpert rapid molecular diagnostic platform, Cepheid has extended its near-patient testing capabilities into BSI-relevant pathogen panels, with particular strength in MRSA and C. difficile detection across hospital settings.
F. Hoffmann-La Roche Ltd.: Roche's molecular diagnostics division supports BSI testing through cobas and LightCycler platform integrations, with pipeline emphasis on automation, throughput scalability, and digital pathology connectivity across high-volume reference laboratories.
Bruker Corporation: A leader in MALDI-TOF mass spectrometry systems, Bruker's MALDI Biotyper platform is deployed in thousands of clinical microbiology laboratories globally, offering rapid species-level identification from positive blood culture material.
Thermo Fisher Scientific: Through its Applied Biosystems and Ion Torrent divisions, Thermo Fisher is advancing next-generation sequencing-based approaches to BSI diagnostics, positioning for clinical whole-genome sequencing workflows in resistance profiling.
Becton Dickinson Medical Devices Co. Ltd.: Becton Dickinson's BD BACTEC blood culture system remains among the most widely deployed automated culture platforms globally, with ongoing integration of molecular identification add-on workflows and digital connectivity through BD Kiestra.
Accelerate Diagnostics Inc.: A technology innovator offering the Accelerate Pheno system, which delivers rapid phenotypic antimicrobial susceptibility testing directly from positive blood cultures in approximately 7 hours, addressing a critical clinical gap between identification and therapy optimization.

Recent Developments & Milestones in Blood Stream Infection Testing Market

January 2023: bioMérieux SA received expanded CE-IVD marking for its BioFire FilmArray Blood Culture Identification 2 (BCID2) panel, adding coverage for additional Gram-negative resistance markers including OXA-48-like carbapenemase genes, strengthening its AMR profiling capability.
March 2023: Accelerate Diagnostics Inc. announced a strategic distribution partnership with a major European in vitro diagnostics distributor to expand Accelerate Pheno system placements across Central and Eastern European acute care hospitals.
June 2023: Thermo Fisher Scientific unveiled its Ion Torrent Genexus Integrated Sequencer enhancements targeting clinical metagenomics workflows for bloodstream infection pathogen identification, signaling NGS-based BSI diagnostics commercialization intent.
September 2023: Becton Dickinson received FDA 510(k) clearance for an updated BD BACTEC FX400 automation interface module, improving throughput and positive culture flagging speed in high-volume clinical laboratory settings.
February 2024: Abbott Laboratories announced integration of its Alinity m molecular platform with AI-assisted result interpretation software for polymicrobial BSI panel results, targeting reduction in diagnostic ambiguity in complex clinical presentations.
May 2024: Bruker Corporation reported a 12% year-over-year increase in MALDI Biotyper clinical system placements globally, driven particularly by hospital network expansions in India, Brazil, and Southeast Asia.
October 2024: The U.S. Centers for Disease Control and Prevention (CDC) updated its Bloodstream Infection prevention guidelines, explicitly recommending rapid molecular panel testing as a standard-of-care complement to blood culture in ICU settings, providing a regulatory tailwind for technology adoption.

Regional Market Breakdown for Blood Stream Infection Testing Market

Sustainability & ESG Pressures on Blood Stream Infection Testing Market

Circular economy mandates in Germany, France, and Scandinavian markets are driving demand for reagent container take-back programs

Blood Stream Infection Testing Market Segmentation

1. Product
- 1.1. Instruments
- 1.2. Consumables
- 1.3. Software and Services
2. Technique
- 2.1. Conventional
- 2.2. Automated
3. Technology
- 3.1. Culture-based
- 3.2. Molecular
- 3.3. Proteomic
4. Application
- 4.1. Bacterial
- 4.2. Fungal
- 4.3. Mycobacterial
5. End-users
- 5.1. Hospitals
- 5.2. Independent Diagnostics Centers
- 5.3. Others

Blood Stream Infection Testing Market Segmentation By Geography

1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
2. South America
- 2.1. Brazil
- 2.2. Argentina
- 2.3. Rest of South America
3. Europe
- 3.1. United Kingdom
- 3.2. Germany
- 3.3. France
- 3.4. Italy
- 3.5. Spain
- 3.6. Russia
- 3.7. Benelux
- 3.8. Nordics
- 3.9. Rest of Europe
4. Middle East & Africa
- 4.1. Turkey
- 4.2. Israel
- 4.3. GCC
- 4.4. North Africa
- 4.5. South Africa
- 4.6. Rest of Middle East & Africa
5. Asia Pacific
- 5.1. China
- 5.2. India
- 5.3. Japan
- 5.4. South Korea
- 5.5. ASEAN
- 5.6. Oceania
- 5.7. Rest of Asia Pacific

Blood Stream Infection Testing Market Regional Market Share

Higher Coverage

Lower Coverage

No Coverage

Aspects	Details
Study Period	2020-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2020-2025
Growth Rate	CAGR of 8.3% from 2020-2034
Segmentation	By Product Instruments Consumables Software and Services By Technique Conventional Automated By Technology Culture-based Molecular Proteomic By Application Bacterial Fungal Mycobacterial By End-users Hospitals Independent Diagnostics Centers Others By Geography North America United States Canada Mexico South America Brazil Argentina Rest of South America Europe United Kingdom Germany France Italy Spain Russia Benelux Nordics Rest of Europe Middle East & Africa Turkey Israel GCC North Africa South Africa Rest of Middle East & Africa Asia Pacific China India Japan South Korea ASEAN Oceania Rest of Asia Pacific

Tailored for you